KemPharm Inc. shares plummeted in the extended session Thursday after a Food and Drug Administration advisory committee did not recommend that abuse-deterrent labeling be added to the drug maker’s painkiller. KemPharm shares dropped 60% to $6.33 after hours. While the FDA committee members voted 16 to 4 to recommend KemPharm’s Apadaz pankiller be approved by the agency, members also voted 18 to 2 recommending against labeling saying that the drug was designed to prevent its abuse. The FDA is not bound to recommendations its committees make but generally goes along with their recommendations.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News